$304.76
0.81%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Stock price

$304.76
+7.20 2.42% 1M
-15.29 4.78% 6M
-48.08 13.63% YTD
-55.46 15.40% 1Y
+87.27 40.13% 3Y
+197.80 184.93% 5Y
+154.14 102.34% 10Y
+269.83 772.36% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-2.48 0.81%

Key metrics

Basic
Market capitalization
$13.8b
Enterprise Value
$10.7b
Net debt
positive
Cash
$3.0b
Shares outstanding
45.2m
Valuation (TTM | estimate)
P/E
11.9 | 11.0
P/S
4.5 | 4.2
EV/Sales
3.5 | 3.3
EV/FCF
10.0
P/B
1.9
Financial Health
Equity Ratio
87.5%
Return on Equity
18.6%
ROCE
20.9%
ROIC
27.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $3.3b
EBITDA
$1.6b | $1.7b
EBIT
$1.5b | $1.6b
Net Income
$1.2b | $1.3b
Free Cash Flow
$1.1b
Growth (TTM | estimate)
Revenue
17.6% | 13.9%
EBITDA
22.4% | 12.7%
EBIT
22.0% | 11.3%
Net Income
16.1% | 4.8%
Free Cash Flow
22.0%
Margin (TTM | estimate)
Gross
89.0%
EBITDA
52.7% | 52.3%
EBIT
50.1%
Net
40.4% | 38.2%
Free Cash Flow
34.8%
More
EPS
$25.7
FCF per Share
$23.7
Short interest
8.3%
Employees
1k
Rev per Employee
$2.2m
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a United Therapeutics Corporation forecast:

14x Buy
67%
7x Hold
33%

Analyst Opinions

21 Analysts have issued a United Therapeutics Corporation forecast:

Buy
67%
Hold
33%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,078 3,078
18% 18%
100%
- Direct Costs 339 339
16% 16%
11%
2,739 2,739
18% 18%
89%
- Selling and Administrative Expenses 678 678
17% 17%
22%
- Research and Development Expense 520 520
8% 8%
17%
1,621 1,621
22% 22%
53%
- Depreciation and Amortization 80 80
31% 31%
3%
EBIT (Operating Income) EBIT 1,541 1,541
22% 22%
50%
Net Profit 1,242 1,242
16% 16%
40%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Neutral
Business Wire
3 days ago
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The ...
Positive
Seeking Alpha
5 days ago
United Therapeutics Corporation remains a Buy as it robustly defends its PAH franchise, counters competitive threats, and posts strong Q2 results with double-digit growth. Upcoming TETON-2 data for Tyvaso in IPF in September is a major catalyst; success could secure label expansion and reinforce United's market dominance. Management is confident in Tyvaso's advantages over rivals and is optimis...
Neutral
Business Wire
about one month ago
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that it will enter today into two Accelerated Share Repurchase (ASR) agreements with Citibank, N.A. (Citi) to repurchase an aggregate $1 billion of UTHR common stock. United Therapeutics will repurchase these shares under the $1 billion repu...
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,305
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today